Why the study?
SARS-CoV-2 suppresses ACE2, increasing inflammatory Angiotensin II effects on the lung and heart, highlighting the need to evaluate ARBs and ACEIs in COVID-19.
This review provides a mechanistic rationale for continuing ACE inhibitors and ARBs in patients with COVID-19, as they may protect against acute lung and cardiac injury.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lumbers et al. (2020) conducted a review in COVID-19. Angiotensin receptor blockers and ACE inhibitors was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: